Harmane-d2

Harmane-d2 is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM) . Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively) [1][2][3][4].

Product Specifications

UNSPSC

12352005

Target

Adrenergic Receptor; Imidazoline Receptor; Isotope-Labeled Compounds; Monoamine Oxidase

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Solubility

10 mM in DMSO

Smiles

CC1=NC([2H])=C([2H])C2=C1NC3=C2C=CC=C3

Molecular Formula

C12H8D2N2

Molecular Weight

184.23

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Louis ED, et, al. Blood harmane concentrations and dietary protein consumption in essential tremor. Neurology. 2005 Aug 9;65 (3) :391-6.|[3]Musgrave IF, et, al. Harmane produces hypotension following microinjection into the RVLM: possible role of I (1) -imidazoline receptors. Br J Pharmacol. 2000 Mar;129 (6) :1057-9.|[4]Glover V, et, al. β-Carbolines as selective monoamine oxidase inhibitors:In vivo implications|[5]Umezawa K, et, al. Comutagenic effect of norharman and harman with 2-acetylaminofluorene derivatives. Proc Natl Acad Sci U S A. 1978 Feb;75 (2) :928-30.